Cargando…
HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer
Rationale: Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with a dismal 5-year survival less than 10%. Most patients with PDAC exhibit poor response to single-agent immunotherapy. Multimodal therapies targeting mechanisms of resistance to immunotherapy are urgently needed. We found that...
Autores principales: | Zhou, Yingke, Jin, Xin, Yu, Haixin, Qin, Gengdu, Pan, Penglin, Zhao, Jingyuan, Chen, Taoyu, Liang, Xueyi, Sun, Yan, Wang, Bo, Ren, Dianyun, Zhu, Shikai, Wu, Heshui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899586/ https://www.ncbi.nlm.nih.gov/pubmed/35265200 http://dx.doi.org/10.7150/thno.69444 |
Ejemplares similares
-
HDAC5 Loss Enhances Phospholipid-Derived Arachidonic Acid Generation and Confers Sensitivity to cPLA2 Inhibition in Pancreatic Cancer
por: Pan, Penglin, et al.
Publicado: (2022) -
Prognostic Analysis of Different Metastatic Patterns in Invasive Intraductal Papillary Mucinous Neoplasm: A Surveillance, Epidemiology, and End Results Database Analysis
por: Zhou, Chen, et al.
Publicado: (2021) -
Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer
por: Sun, Yan, et al.
Publicado: (2021) -
NR5A2 transcriptional activation by BRD4 promotes pancreatic cancer progression by upregulating GDF15
por: Guo, Feng, et al.
Publicado: (2021) -
MST2 methylation by PRMT5 inhibits Hippo signaling and promotes pancreatic cancer progression
por: Sun, Yan, et al.
Publicado: (2023)